SG11201804263PA - Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor - Google Patents
Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitorInfo
- Publication number
- SG11201804263PA SG11201804263PA SG11201804263PA SG11201804263PA SG11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA
- Authority
- SG
- Singapore
- Prior art keywords
- bothell
- drive
- international
- washington
- fucose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ristspi id (43) International Publication Date .... .....r ,„„0 8 June 2017 (08.06.2017) W I P0 1 PCT ID Hit (10) 11111111 WO Ill International 1111111111 IIIII II 2017/096274 III IIIIIIIIIIIIIII Publication IIIIIIIIIIIIII Al Number RIO IIII IIIIIIII (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/7024 (2006.01) A61K 39/395 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/7042 (2006.01) C07K 16/28 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/70 (2006.01) C07K 16/32 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 31/02 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US2016/064783 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 2 December 2016 (02.12.2016) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/263,228 4 December 2015 (04.12.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/308,583 15 March 2016 (15.03.2016) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/321,857 13 April 2016 (13.04.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: SEATTLE GENETICS, INC. [US/US]; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 21823 30th Drive SE, Bothell, Washington 98021 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: GARDAI, Shyra; 21823 30th Drive SE, GW, KM, ML, MR, NE, SN, TD, TG). Bothell, Washington 98021 (US). LAW, Che-Leung; Declarations under Rule 4.17: 21823 30th Drive SE, Bothell, Washington 98021 (US). be — as to applicant's entitlement to apply for and granted a SENTER, Peter; 21823 30th Drive SE, Bothell, Washing- patent (Rule 4.170) ton 98021 (US). OKELEY, Nicole; 21823 30th Drive SE, Bothell, Washington 98021 (US). FIELD, Jessica; 21823 — as to the applicant's entitlement to claim the priority of the 30th Drive SE, Bothell, Washington 98021 (US). earlier application (Rule 4.17(iii)) (74) Agents: LIN, Min al.; Seattle Genetics, Inc., 21823 30th Published: et Drive SE, Bothell, Washington 98021 (US). — with international search report (Art 21(3)) Title: CANCER TREATMENT USING 2-DEOXY-2-FLUORO-L-FUCOSE IN COMBINATION WITH A CHECKPOINT (54) INHIBITOR Figure 11 100 AP- Untreated -M-2FF To 80- -A- Anti-PD1 91 60- m -0- 2FF + Anti-PD1 Cl) . 6' 1-1 a) 40 - .4t 2 a) il• 0 - 20- 11\" - - el 0. . . . C) 0 01 0 IN 1-1 O (57) : The present invention is an effective amount of 2-deoxy-2-fluoro-L-fucose 0 with a checkpoint inhibitor. 20 40 60 80 100 Days post tumor implant directed to methods for treating cancer comprising administering to a subject in need thereof or a prodrug thereof, or a pharmaceutically acceptable salt thereof, in combination
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562263228P | 2015-12-04 | 2015-12-04 | |
US201662308583P | 2016-03-15 | 2016-03-15 | |
US201662321857P | 2016-04-13 | 2016-04-13 | |
PCT/US2016/064783 WO2017096274A1 (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804263PA true SG11201804263PA (en) | 2018-06-28 |
Family
ID=58797961
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804263PA SG11201804263PA (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
SG10202005298RA SG10202005298RA (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202005298RA SG10202005298RA (en) | 2015-12-04 | 2016-12-02 | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
Country Status (13)
Country | Link |
---|---|
US (1) | US20180353524A1 (en) |
EP (1) | EP3383404A4 (en) |
JP (1) | JP6906520B2 (en) |
KR (1) | KR20180086233A (en) |
CN (1) | CN108289903B (en) |
AU (1) | AU2016362993A1 (en) |
BR (1) | BR112018011261A2 (en) |
CA (1) | CA3005997A1 (en) |
EA (1) | EA201891340A1 (en) |
IL (1) | IL259479B (en) |
MX (1) | MX2018006674A (en) |
SG (2) | SG11201804263PA (en) |
WO (1) | WO2017096274A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103402525B (en) | 2010-08-05 | 2017-03-01 | 西雅图基因公司 | The method suppressing protein fucosylation in vivo using fucose analogue |
IL265800B2 (en) | 2016-10-11 | 2023-10-01 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
MA50865A (en) * | 2017-06-07 | 2020-04-15 | Seattle Genetics Inc | REDUCED SURFACE FUCOSYLATION T LYMPHOCYTES AND METHODS FOR THE PRODUCTION AND USE OF THE SAME |
US11911404B2 (en) * | 2017-10-13 | 2024-02-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune surveillance in melanoma |
AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
EP3897664A4 (en) * | 2018-12-19 | 2022-12-07 | Seagen Inc. | Controlled fucosylation of antibodies |
US20220305038A1 (en) * | 2019-08-16 | 2022-09-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
CN111973749B (en) * | 2020-09-07 | 2023-03-21 | 威海人生药业集团股份有限公司 | Pharmaceutical composition for anti-tumor immunotherapy |
WO2022221766A1 (en) * | 2021-04-16 | 2022-10-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
CN113274502B (en) * | 2021-05-05 | 2023-01-03 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Compositions for specific type three-negative breast cancer immunotherapy |
WO2022236017A1 (en) * | 2021-05-06 | 2022-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | L-fucose and anti-androgen receptor therapy for treatment of cancer |
CN113413465B (en) * | 2021-06-15 | 2022-06-03 | 北京大学 | Application of fucosylation inhibitor in resisting inflammation caused by cancer |
CN115466297B (en) * | 2022-08-25 | 2023-07-07 | 青岛农业大学 | Application of L-fucose and animal feed |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103402525B (en) * | 2010-08-05 | 2017-03-01 | 西雅图基因公司 | The method suppressing protein fucosylation in vivo using fucose analogue |
WO2015069770A1 (en) | 2013-11-05 | 2015-05-14 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
-
2016
- 2016-12-02 EP EP16871645.4A patent/EP3383404A4/en not_active Withdrawn
- 2016-12-02 EA EA201891340A patent/EA201891340A1/en unknown
- 2016-12-02 SG SG11201804263PA patent/SG11201804263PA/en unknown
- 2016-12-02 AU AU2016362993A patent/AU2016362993A1/en not_active Abandoned
- 2016-12-02 BR BR112018011261A patent/BR112018011261A2/en not_active Application Discontinuation
- 2016-12-02 CN CN201680071076.0A patent/CN108289903B/en not_active Expired - Fee Related
- 2016-12-02 JP JP2018528650A patent/JP6906520B2/en active Active
- 2016-12-02 SG SG10202005298RA patent/SG10202005298RA/en unknown
- 2016-12-02 WO PCT/US2016/064783 patent/WO2017096274A1/en active Application Filing
- 2016-12-02 KR KR1020187017824A patent/KR20180086233A/en unknown
- 2016-12-02 CA CA3005997A patent/CA3005997A1/en not_active Abandoned
- 2016-12-02 MX MX2018006674A patent/MX2018006674A/en unknown
- 2016-12-02 US US15/781,256 patent/US20180353524A1/en not_active Abandoned
-
2018
- 2018-05-21 IL IL259479A patent/IL259479B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2019501145A (en) | 2019-01-17 |
CA3005997A1 (en) | 2017-06-08 |
CN108289903A (en) | 2018-07-17 |
JP6906520B2 (en) | 2021-07-21 |
EA201891340A1 (en) | 2018-11-30 |
MX2018006674A (en) | 2018-11-09 |
EP3383404A4 (en) | 2019-07-31 |
BR112018011261A2 (en) | 2018-11-21 |
CN108289903B (en) | 2021-08-03 |
IL259479B (en) | 2022-03-01 |
US20180353524A1 (en) | 2018-12-13 |
WO2017096274A1 (en) | 2017-06-08 |
EP3383404A1 (en) | 2018-10-10 |
IL259479A (en) | 2018-07-31 |
KR20180086233A (en) | 2018-07-30 |
SG10202005298RA (en) | 2020-07-29 |
AU2016362993A1 (en) | 2018-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201808676RA (en) | Methods of treating pediatric cancers | |
SG11201805755SA (en) | Methods of administering hepcidin | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
SG11201804268RA (en) | Conjugates of quaternized tubulysin compounds | |
SG11201804587QA (en) | Isoindole compounds | |
SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
SG11201810940XA (en) | Methods of treating pancreatic cancer | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |